Circulating proteins to predict COVID-19 severity
- PMID: 37069249
- PMCID: PMC10107586
- DOI: 10.1038/s41598-023-31850-y
Circulating proteins to predict COVID-19 severity
Abstract
Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including protein abundances and clinical risk factors to predict COVID-19 severity in 417 subjects and tested these models in a separate cohort of 569 individuals. For severe COVID-19, a baseline model including age and sex provided an area under the receiver operator curve (AUC) of 65% in the test cohort. Selecting 92 proteins from the 4701 unique protein abundances improved the AUC to 88% in the training cohort, which remained relatively stable in the testing cohort at 86%, suggesting good generalizability. Proteins selected from different COVID-19 severity were enriched for cytokine and cytokine receptors, but more than half of the enriched pathways were not immune-related. Taken together, these findings suggest that circulating proteins measured at early stages of disease progression are reasonably accurate predictors of COVID-19 severity. Further research is needed to understand how to incorporate protein measurement into clinical care.
© 2023. The Author(s).
Conflict of interest statement
J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital and is the Founder of 5 Prime Sciences. The Lady Davis Institute has previously received funding from GlaxoSmithKline, Eli Lilly, and Biogen for research programs at Dr. Richards’ laboratory unrelated to this manuscript. C.P. and M.H. are employees of SomaLogic. All other authors do not have any conflict of interest. TN has received speaking fees from Boehringer Ingelheim for talks unrelated to this research. S.G. reports other research funding from Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Genentech, Regeneron, and Takeda. S.G. reports other research funding from Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Genentech, Regeneron, and Takeda.
Figures



Similar articles
-
Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study.Int J Epidemiol. 2021 Mar 3;50(1):64-74. doi: 10.1093/ije/dyaa209. Int J Epidemiol. 2021. PMID: 33349845 Free PMC article.
-
Lymphocyte-monocyte-neutrophil index: a predictor of severity of coronavirus disease 2019 patients produced by sparse principal component analysis.Virol J. 2021 Jun 4;18(1):115. doi: 10.1186/s12985-021-01561-9. Virol J. 2021. PMID: 34088324 Free PMC article.
-
Uncovering Clinical Risk Factors and Predicting Severe COVID-19 Cases Using UK Biobank Data: Machine Learning Approach.JMIR Public Health Surveill. 2021 Sep 30;7(9):e29544. doi: 10.2196/29544. JMIR Public Health Surveill. 2021. PMID: 34591027 Free PMC article.
-
Using Predictive Models to Improve Care for Patients Hospitalized with COVID-19 [Internet].Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2023 Jan. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2023 Jan. PMID: 38976624 Free Books & Documents. Review.
-
Predicting clinical outcomes among hospitalized COVID-19 patients using both local and published models.BMC Med Inform Decis Mak. 2021 Jul 24;21(1):224. doi: 10.1186/s12911-021-01576-w. BMC Med Inform Decis Mak. 2021. PMID: 34303356 Free PMC article. Review.
Cited by
-
Impact and prevalence of comorbidities and complications on the severity of COVID-19 in association with age, gender, obesity, and pre-existing smoking: A meta-analysis.Biomedicine (Taipei). 2024 Mar 1;14(1):20-38. doi: 10.37796/2211-8039.1429. eCollection 2024. Biomedicine (Taipei). 2024. PMID: 38533301 Free PMC article. Review.
-
Proteomics validate circulating GDF-15 as an independent biomarker for COVID-19 severity.Front Immunol. 2024 Apr 15;15:1377126. doi: 10.3389/fimmu.2024.1377126. eCollection 2024. Front Immunol. 2024. PMID: 38686386 Free PMC article.
-
Unraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA-Protein Networks.Int J Mol Sci. 2025 May 6;26(9):4412. doi: 10.3390/ijms26094412. Int J Mol Sci. 2025. PMID: 40362649 Free PMC article.
-
Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19.Cell Rep Med. 2024 Jul 16;5(7):101642. doi: 10.1016/j.xcrm.2024.101642. Epub 2024 Jul 8. Cell Rep Med. 2024. PMID: 38981485 Free PMC article.
-
Extracellular acyl-CoA-binding protein as an independent biomarker of COVID-19 disease severity.Front Immunol. 2025 Jan 6;15:1505752. doi: 10.3389/fimmu.2024.1505752. eCollection 2024. Front Immunol. 2025. PMID: 39835130 Free PMC article.
References
-
- The COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis. medRxiv (2021) doi:10.1101/2021.03.10.21252820.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical